Top of page

CheckMate 436: a phase 1/2 trial testing nivolumab with brentuximab vedotin for people with relapsed or refractory non-Hodgkin lymphoma

People with diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBL) or mediastinal grey zone lymphoma (grey zone lymphoma that is behind your sternum in your chest) might be able to enter this trial. 

Note: This trial is now only recruiting participants with mediastinal grey zone lymphoma.


Purpose of trial

The aim of this trial is to test if the combination of nivolumab and brentuximab vedotin is safe and effective for people with certain types of non-Hodgkin lymphoma.


Treatments

Nivolumab is an immune checkpoint inhibitor – it works by helping the immune system recognise and attack the lymphoma.

Brentuximab vedotin is an antibody joined to a strong chemotherapy drug – an antibody-drug conjugate. It is already used to treat some types of lymphoma.

Everyone in this trial has nivolumab and brentuximab vedotin.

Both drugs are given intravenously (through a drip into a vein). Treatment is given in cycles of 3 weeks. In the first cycle:

  • brentuximab vedotin is given on day 1
  • nivolumab is given on day 8.

After that, both drugs are given on day 1 of each cycle. You continue to receive both drugs for as long as they are helping you.


Who can enter

Your consultant can give you advice on whether this trial might be suitable for you.

Around 90 people are needed for this trial.

You may be able to enter if:

  • You have diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBL) or mediastinal grey zone lymphoma (grey zone lymphoma that is behind your sternum in your chest).
  • Your lymphoma has relapsed (come back) or was refractory (didn’t respond) to previous treatment).
  • Your lymphoma cells have a protein called ‘CD30’, which is the target for brentuximab vedotin.
  • You are 18 or over.

You will not be able to enter if:

  • You have any health problems that your doctor thinks might make it unsafe for you to have the trial treatment.
  • Your lymphoma is in your central nervous system (CNS; brain and spinal cord).
  • You have an autoimmune disease (a disease where your body attacks itself). Your doctor can advise if this applies to you.

Further information

More information about this trial is available at clinicaltrials.gov.